ProCE Banner Activity

Mastering the Evolving Treatment Landscape in HER2-Positive Breast Cancer: Current Guidance and Future Perspectives

Slideset Download
Download this slideset from a workshop series to learn more about the latest evidence on managing HER2-postive breast cancer from the neoadjuvant setting through metastatic disease.

Released: April 12, 2022

Expiration: April 11, 2023

No longer available for credit.

Share

Faculty

Aditya Bardia

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

Claudine Isaacs

Claudine Isaacs, MD

Professor of Medicine and Oncology
Associate Director for Clinical Research
Georgetown University
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Puma Biotechnology, Inc.

Seagen Inc.

Faculty Disclosure

Primary Author

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

Aditya Bardia, MD, MPH, has disclosed that he has received consulting fees from Daiichi Sankyo, Eli Lilly, Foundation Medicine, Genentech, Immunomedics/Gilead Sciences, Merck, Novartis, Pfizer, Pharma/AstraZeneca, Phillips, Radius Health, and Sanofi and funds for research support from Daiichi Sankyo, Genentech, Immunomedics/Gilead Sciences, Lilly, Merck, Natera, Novartis, Pharma/AstraZeneca, Pfizer, Radium Health, and Sanofi.

Claudine Isaacs, MD

Professor of Medicine and Oncology
Associate Director for Clinical Research
Georgetown University
Washington, DC

Claudine Isaacs, MD, has disclosed that she has received consulting fees from AmerisourceBergen, AstraZeneca, Biotheranostics, Eisai, Genentech, Immunomedics, Novartis, Pfizer, Puma, Sanofi, and Seagen.